BioMed Research International / 2018 / Article / Tab 2 / Research Article
Infections Caused by Extended-Spectrum β -Lactamase Producing Escherichia Coli in Systemic Lupus Erythematosus Patients: Prevalence, Risk Factors, and Predictive Model Table 2 The antimicrobial susceptibility patterns of ESBL producing and nonproducing strains to various antimicrobials, n(%).
Antibiotics Total ESBL (+) ESBL (-) P valuen=384 n=212 n=172 Ampicillin 46 (11.9) 0 (0) 46 (27.8) <0.001 Piperacillin 54 (14.1) 0 (0) 54 (31.4) <0.001 Ampicillin-sulbactam 120 (31.3) 26 (12.3) 94 (54.7) <0.001 Piperacillin-tazobactam 346 (90.1) 174 (82.1) 172 (100) <0.001 Ciprofloxacin 110 (28.6) 20 (9.4) 90 (52.3) <0.001 Levofloxacin 70 (18.2) 0 (0) 70 (40.7) <0.001 cefuroxime 114 (29.7) 0 (0) 114 (66.3) <0.001 ceftazidime 228 (59.4) 56 (26.4) 172 (100) <0.001 cefepime 226 (58.9) 80 (37.7) 146 (84.9) <0.001 Aztreonam 260 (67.7) 88 (41.5) 172 (100) <0.001 Amikacin 354 (92.2) 190 (89.6) 164 (95.3) 0.230 Gentamicin 214 (55.7) 100 (47.2) 114 (66.3) 0.008 Fosfomycin 310 (80.7) 138 (65.1) 172 (100) <0.001 Trimethoprim-sulfamethoxazole 140 (36.5) 58 (27.4) 82 (47.7) 0.004 Ertapenem 344 (89.6) 172 (81.1) 172 (100) <0.001 Meropenem 378 (98.4) 206 (97.2) 172 (100) 0.254 Imipenem 378 (98.4) 206 (97.2) 172 (100) 0.254
ESBL, Extended-Spectrum
-Lactamase.